Epigenetics and precision medicine in cardiovascular patients

from basic concepts to the clinical arena

Sarah Costantino, Peter Libby, Raj Kishore, Jean Claude Tardif, Assam El-Osta, Francesco Paneni

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12% to 20% compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners 'eyeball' assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for 'precision medicine'. Yet the inherited genome determines only part of an individual's risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the 'epi'genome. Epigenetic modifications defined as 'heritable changes to the genome that do not involve changes in DNA sequence' have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine.

Original languageEnglish
Pages (from-to)4150-4158
Number of pages9
JournalEuropean Heart Journal
Volume39
Issue number47
DOIs
Publication statusPublished - 14 Dec 2018

Cite this

Costantino, Sarah ; Libby, Peter ; Kishore, Raj ; Tardif, Jean Claude ; El-Osta, Assam ; Paneni, Francesco. / Epigenetics and precision medicine in cardiovascular patients : from basic concepts to the clinical arena. In: European Heart Journal. 2018 ; Vol. 39, No. 47. pp. 4150-4158.
@article{62cc8d65cff6428e982a7006c3a2a50c,
title = "Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena",
abstract = "Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12{\%} to 20{\%} compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners 'eyeball' assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for 'precision medicine'. Yet the inherited genome determines only part of an individual's risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the 'epi'genome. Epigenetic modifications defined as 'heritable changes to the genome that do not involve changes in DNA sequence' have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine.",
author = "Sarah Costantino and Peter Libby and Raj Kishore and Tardif, {Jean Claude} and Assam El-Osta and Francesco Paneni",
year = "2018",
month = "12",
day = "14",
doi = "10.1093/eurheartj/ehx568",
language = "English",
volume = "39",
pages = "4150--4158",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "47",

}

Epigenetics and precision medicine in cardiovascular patients : from basic concepts to the clinical arena. / Costantino, Sarah; Libby, Peter; Kishore, Raj; Tardif, Jean Claude; El-Osta, Assam; Paneni, Francesco.

In: European Heart Journal, Vol. 39, No. 47, 14.12.2018, p. 4150-4158.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Epigenetics and precision medicine in cardiovascular patients

T2 - from basic concepts to the clinical arena

AU - Costantino, Sarah

AU - Libby, Peter

AU - Kishore, Raj

AU - Tardif, Jean Claude

AU - El-Osta, Assam

AU - Paneni, Francesco

PY - 2018/12/14

Y1 - 2018/12/14

N2 - Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12% to 20% compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners 'eyeball' assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for 'precision medicine'. Yet the inherited genome determines only part of an individual's risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the 'epi'genome. Epigenetic modifications defined as 'heritable changes to the genome that do not involve changes in DNA sequence' have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine.

AB - Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12% to 20% compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners 'eyeball' assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for 'precision medicine'. Yet the inherited genome determines only part of an individual's risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the 'epi'genome. Epigenetic modifications defined as 'heritable changes to the genome that do not involve changes in DNA sequence' have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine.

UR - http://www.scopus.com/inward/record.url?scp=85058889159&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehx568

DO - 10.1093/eurheartj/ehx568

M3 - Article

VL - 39

SP - 4150

EP - 4158

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 47

ER -